JOIN US FOR THE 2025 ZERO PROSTATE CANCER EDUCATION & SUPPORT SUMMIT!

Dustin Nowaskie, MD

OutCare Health

Dustin Nowaskie, MD (they/them/theirs) Dr. Nowaskie is a queer, nonbinary psychiatrist. Their personal identification and civic commitment have cultivated into a passion to help LGBTQ+ communities. They are the Founder, President, and Chief Medical Officer of the national nonprofit LGBTQ+ health equity organization OutCare Health, which provides access to LGBTQ+ information, resources, programming, mentorship, education, training, research, and providers for millions across the world. A Summa Cum Laude and Phi Beta Kappa graduate of the University of Southern California and Gold Humanism Honor Scholar of the Indiana University School of Medicine, Dr. Nowaskie’s clinical and philanthropic work has led to several national accolades, presentations, and publications as well as diversity awards from the Jack Kent Cooke Foundation, American Medical Association, Tylenol Future Care Foundation, Gamma Mu Foundation, Association of LGBTQ+ Psychiatrists, World Professional Association for Transgender Health, and Out to Innovate. Their ultimate goal is to transform their might into a powerful unicorn of social and public health change for LGBTQ+ people.

Jonathan Leeman, MD

Dana-Farber Brigham Cancer Center

Dr. Leeman is an Assistant Professor of Radiation Oncology at Harvard Medical School and serves as the director of MRI guided and adaptive radiotherapy at the Dana-Farber Brigham Cancer Center in Boston, MA. He received his AB from Harvard College and is a graduate of the Physician Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his internship and residency in radiation oncology at Memorial Sloan Kettering Cancer Center in New York, NY where he served as Chief Resident. His clinical expertise lies in the areas of MRI guided radiotherapy, adaptive radiotherapy and prostate cancer. His research focuses on the application of MR imaging technology and adaptive radiotherapy for the advancement of prostate cancer treatment to improve treatment outcomes by reducing side effects of treatment and improving disease control for patients at all stages of disease.

Jeffrey Albaugh, PhD, APRN, CUCNS

Dr. Jeffrey Albaugh is a board-certified Advanced Practice Urology Clinical Nurse Specialist, researcher, and author based in Chicago with over 30 years of experience caring for individuals with sexual dysfunction. He is also a Certified Sexuality Counselor. He hosts his own podcast "Dr. Jeff Talks about Sex & Intimacy on Tuesday evenings at 7PM. Dr. Albaugh has his own clinc at the Jesse Brown VA Medical Center, serving Veterans. Previously, he was the Director of Sexual Health at Endeavor/NorthShore University HealthSystem and held a similar role at Northwestern Memorial Hospital. His NIH-funded PhD research at the University of Illinois in Chicago focused on quality of life in men with sexual dysfunction following prostatectomy for prostate cancer. An internationally recognized expert and speaker, Dr. Albaugh has presented across the United States and in countries including Spain, Italy, Scotland, Ireland, New Zealand, and Australia. A prolific author, he has contributed numerous peer-reviewed articles, book chapters, and published his own books including "Reclaiming Sex & Intimacy after Prostate Cancer 2nd Edition".. His contributions have been recognized with multiple honors, including nursing excellence awards, SUNA President’s Awards, the Patient’s First Award from Northwestern, and the Edward C. Kaps Hope Award for his work with men facing prostate cancer. A trusted voice in the media, Dr. Albaugh has been featured on WGN News, CBS 2 Chicago, and in the Chicago Tribune, where he was highlighted in the “Ask the Expert” column.

Joseph D. Shirk, MD

Greater Los Angeles VA Health System David Geffen School of Medicine at UCLA

Joseph D. Shirk, MD is the Chief of Urology and Director of the Clinical Procedures Center at the Greater Los Angeles VA Health System and Assistant Professor of Urology at the David Geffen School of Medicine at UCLA.Dr. Shirk earned his medical degree from the Medical College of Wisconsin. He completed his intern year at Boston Medical Center and subsequently completed his urology residency at the University of California, Los Angeles (UCLA) and urologic oncology fellowship training at UCLA’s Institute of Urologic Oncology (IUO) and David Geffen School of Medicine.Dr. Shirk performs complex urologic oncology operations, including robotic prostatectomy, cystectomy, partial nephrectomy, retroperitoneal lymph node dissection, and tumor thrombectomy. His primary research interests include the development and use of advanced, innovative imaging techniques.  He is the cofounder of Ceevra, Inc, which is a company that has developed an AI driven platform to create 3D, digital images that surgeons use to guide their operations.

Elisabeth Heath, MD, FACP

Mayo Clinic

Dr. Elisabeth Heath is a nationally and internationally recognized expert in genitourinary oncology, serving as the Chair of the Department of Oncology at the Mayo Clinic in Rochester, MN. She specializes in clinical and translational research, focusing on early-phase and genitourinary clinical trials and addressing important health disparities. Her expertise covers a range of genitourinary cancers, including prostate, kidney, and bladder cancer.

In addition to her clinical work, Dr. Heath has led large-scale, multi-institutional, peer-reviewed research initiatives aimed at fostering collaboration across medical disciplines. Her goal is to integrate research and clinical practice, translating scientific discoveries into real-world treatments.

Dr. Heath is also committed to improving patient access to care and their experience during treatment. She emphasizes collaboration within multidisciplinary teams to achieve holistic, effective patient outcomes. Her leadership and innovative approaches have advanced the understanding and treatment of genitourinary cancers while shaping cancer care practices both nationally and internationally. Through her work, Dr. Heath continues to contribute significantly to the oncology community, with a focus on patient-centered care and health equity.

Alicia Morgans, MD

Dana-Farber Cancer Institute

Dr. Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. As a clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and her work has been funded by grants from the Prostate Cancer Foundation , the National Comprehensive Cancer Network, and the Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for prostate cancer patients, and has participated in the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and the cardio-oncology committee of American Heart Association.  

Jason Hafron, MD

Michigan Urology

Dr. Hafron is the Chief Medical Officer and Medical Director of Clinical Research at the Michigan Institute of Urology (MIU). Dr. Hafron is a Professor of Urology at the William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan. He is experienced in all areas of adult urology, specializing in prostate, kidney, and bladder cancer.

Dr. Hafron received his Bachelor of Science degree from the University of Michigan and his Doctor of Medicine from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Surgery and Urology Residency at Albert Einstein College of Medicine, Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, Ohio.

Dr. Hafron has published numerous peer-reviewed journal articles on topics related to his expertise and has presented his work at many national and international scientific meetings. He is the recipient of many clinical research awards. He is on the Editorial Board of the journal International Urology and Nephrology, Urologists in Cancer Care and Urology Times. He previously served on the Board of Directors of the United Physicians Organization and currently serves on the Board of Directors for LUGPA, Michigan Men’s Health Foundation and

FORCE-Facing Hereditary Cancer EMPOWERED. Dr. Hafron is board-certified in the specialty of Urology by the American Board of Urology.

Charles "Chuck" Ryan, MD

Memorial Sloan Kettering Cancer Center

Charles J. Ryan, MD, is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of and supportive care of all men with prostate cancer, seeing patients at Memorial Sloan Kettering Cancer Center in New York. Dr. Ryan earned a BA in Philosophy, magna cum laude, from Marquette University and graduated from the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics, and at Memorial Sloan Kettering Cancer Center. 

As faculty at the University of California-San Francisco, he was named the Thomas Perkins Distinguished Professor in Cancer Research. He has received research funding from the National Institutes of Health, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation. Ryan has published over 200 articles and chapters in the world’s leading medical journals and is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In. Dr. Ryan is a past Chair of the National Cancer Institute’s GU Steering Committee’s Prostate Cancer Task Force. 

From 2018 to 2021 he served as Director of the Division of Hematology, Oncology and Transplantation at the University of Minnesota, where he was the BJ Kennedy Chair in Clinical Oncology. From 2021 to 2024 Ryan served as the CEO of the Prostate Cancer Foundation. He serves on the Scientific Oversight Committee of the Prostate Cancer Clinical Trials Consortium and is a member of the Advanced Prostate Cancer Consensus Conference. Dr. Ryan is a member of ZERO's Medical Advisory Board.

Neal Shore, MD, FACS

Atlantic Urology Clinics

Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer

Advocacy Network, the APCCC Scientific Steering Committee, Maple Tree Cancer Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE,

Urology Practice, JUOP, Everyday Urology Oncology and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology. He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.

Leanne Woods-Burnham, PhD

Morehouse School of Medicine

Dr. Leanne Woods-Burnham is an Assistant Professor in the Department of Surgery at Morehouse School of Medicine in Atlanta, GA. Her team focuses on prostate cancer health disparities. She is a translational scientist, and her team evaluates genetic and molecular drivers of aggressive tumor biology associated with genetic ancestry. Dr. Burnham has fostered several national multidisciplinary collaborations with clinicians and pharma to conduct translational research studies and clinical trials for patients. She co-directs the Prostate Cancer Precision Prevention Program (PCP3) which leverages community partnerships to provide health education and free PSA tests to at-risk men in the greater Atlanta area. Dr. Burnham has been recognized by Cell’s #FacesofCell Twitter campaign to increase visibility of talented Black scientists, as well as The Cancer Health 25: Black Lives Matter, as a “remarkable individual breaking down racial barriers to better cancer care.” In 2025, she has been awarded “Innovator of the Year—Men’s Health” by the Atlanta Business Chronicle and “1,000 Inspiring Black Scientists in America” by Cell MENTOR.

Paul Nakamura

Patient/Survivor

I am a retired engineer and manager, having retired in 2012 after 45 years in electronics, microelectronics and satellite systems.  The last 5 years of my retirement has been a roller coaster ride with many ups and downs.  ZERO has been instrumental in keeping me mostly in the ups.

A ZERO Prostate Cancer advocate and a prostate cancer warrior who was diagnosed in 2020 with Stage 4 cancer, Gleason 9 and mets to bones and outside my prostate and bladder. To say this was "unexpected and a big shock" is an understatement.  Over the last 5 years I’ve gone through many treatments including ADT and extensive radiation sessions. When my cancer became resistant to my treatments in late 2024, I had one chemo infusion and then started Pluvicto treatments. I was fortunate to be selected for a clinical trial at UCLA for Pluvicto, Flexible MRT (control group). I have completed 3 of 6 infusions. So far, my results have been excellent with SpectCT scans showing >90% reduction in tumor size and no new tumors. That’s my path so far on my journey with this unrelenting disease.

Stacey Kenfield, ScD

Professor of Urology,UCSF

Stacey A. Kenfield, ScD received her Bachelor of Science from UCLA in Physiological Science, followed by a Master of Science in Epidemiology, a Doctor of Science in Epidemiology, and a post-doctoral fellowship, all completed at the Harvard T.H. Chan School of Public Health. She continues to lead the Harvard-based Health Professionals Follow-up Study (HPFS) prostate cancer clinical follow-up of more than 7,500 men with prostate cancer since assuming this role in 2005. These data are used to identify factors that may improve prognosis and quality of life. She has worked in cancer epidemiology for the past 10 years and received a Prostate Cancer Foundation Young Investigator Award in 2012. She was recently appointed as the Helen Diller Family Chair in Population Science for Urologic Cancer in 2016.

Monica Bryant, JD

Triage Cancer

Monica Fawzy Bryant is a cancer rights attorney and the co-founder and Chief Operating Officer for Triage Cancer. Monica has dedicated her career to improving access to and availability of quality information on the practical, insurance, financial, and legal issues surrounding serious medical conditions, like cancer. She has provided more than one thousand educational seminars, written articles and co-authored a book published by the American Bar Association called Cancer Rights Law: An Interdisciplinary Approach, as well as appeared on television and radio discussing healthcare related legal issues.  Previously, Monica worked as Legislative Counsel for U.S. Congresswoman Linda T. Sanchez and Law Clerk for U.S. Senator Dianne Feinstein.

Victor LaGroon

Veteran, Former Chief Diversity Officer

Victor LaGroon, recently worked as the Head Consultant of Global Health Equity Strategy at Assurance Health Data. Before assuming his current position, Victor served as the inaugural Chief Diversity Officer at the Office of the Secretary, US Department of Veterans Affairs, the largest healthcare system in the country. With a focus on influencing policy and advocating for the broader Veteran population, Victor brings nearly two decades of experience in academia and healthcare systems, dedicated to advancing health equity for at-risk and underserved communities.

Before joining the Biden Administration, Victor held the role of Director of Strategic Partnerships and Alliances for the Division of Health Equity at the Department of Population Sciences at City of Hope. In Chicago, Victor was the first appointee as the Director of the Mayor's Office of Veterans Affairs for the City of Chicago after several terms serving as the Chairman of the Advisory Council of Veterans Affairs for Mayor Rahm Emanuel and was an active member of the Mayor’s Commission for a Safer Chicago. Additionally, he contributed to statewide efforts as an appointee to the Illinois Joining Forces Foundation Board.

Victor's deep understanding of underserved populations, coupled with an extensive nationwide network of regional non-profit, for-profit, and governmental partners, uniquely equips him to develop effective and transformational programs with a lasting impact on underserved populations.

Victor attributes his commitment to serving people to his time with the 10th Mountain Division, U.S. Army, where he served as an Intelligence Analyst and was medically retired in 2006. A national speaker and advocate, Victor has testified before the 117th Congressional House Veterans Affairs Committee on issues such as access to care, Veterans benefits, transition, and employment strategies, focusing on those from at-risk and underrepresented communities. He previously chaired the Black Veteran Empowerment Council, advocating for policy changes to ensure equitable utilization of benefits for African American Service Members and Veterans.

Leslie Waltke, PT, DPT

Waltke Cancer Rehabilitation Academy

Leslie J. Waltke, PT, DPT is a physical therapist with a clinical mastery in cancer rehabilitation and a provider of world class cancer rehabilitation program development consulting and continuing education. Since earning her degree in Physical Therapy from the University of Wisconsin in 1988, Dr. Waltke has dedicated most of her career solely to treating the cardiopulmonary, musculoskeletal, integumentary and functional needs of persons during and after treatment for cancer. Over the past decades Dr. Waltke has cared for thousands of people with cancer and has a following of beloved patients. She is respected nationally and internationally as an oncology physical therapist, cancer rehabilitation key opinion leader,

author, educator and consultant. Since 2005 Dr. Waltke has been the Cancer Rehabilitation Coordinator for Aurora Health Care, one of

the United States’ largest CoC and NAPBC accredited cancer programs and proud holder of the rare Commission on Cancer “Outstanding Achievement Award.” Her role, in addition to treating patients with cancer, includes cancer rehabilitation program development, program integration, education and training, and best practice and clinical standards development.

A gifted and impassioned speaker, Dr. Waltke teaches and lectures throughout the world with the Waltke Cancer Rehabilitation Academy to rehab professionals, universities, medical and oncology providers, cancer organizations as well as cancer patients and survivors. She spoke at the 2014 China Cancer Congress and the 2015 and 2017 World Cancer Congresses. In 2022 she worked with the World Health Organization to standardize oncologic rehabilitation interventions. Dr. Waltke holds a certificate in Online Education from the University of Wisconsin, is a former Board Member of the Oncology Section of the American Physical Therapy Association, an APTA Credentialed Clinical Instructor, on the Specialization Academy of Content Experts and a is a founding and current board member of ABCD, Inc. (After Breast Cancer Diagnosis). Honors include the “2014 Article of the Year Award” from the Journal of Patient-Centered Research and Reviews, the 2015 Academic Excellence

and Leadership Award from Rosalind Franklin University of Medicine and Science, and the 2015 Physical Medicine and Rehabilitation Education Recognition scholarship. Dr. Waltke is a member of ASCO and ACE, the Association of Cancer Executives. Dr. Waltke’s drive and vision to make the world better for people facing illness led her to OneVillage, where she is honored to serve as Chief Wellness Officer.

Erica Vitek, OT, BCB-PMD, PRPC

Aurora Sinai Medical Center

Erica graduated with her master’s degree in Occupational Therapy from Concordia University Wisconsin in 2002. Erica works full time in hospital-based outpatient rehabilitation at Aurora Sinai Medical Center, part of Aurora Health Care, in downtown Milwaukee, Wisconsin. Erica specializes in male, female, and pediatric evaluation and treatment of the pelvic floor and related bladder, bowel, and sexual health issues. Erica is Board Certified in Biofeedback for Pelvic Muscle Dysfunction (BCB-PMD) through the Biofeedback Certification International Alliance and is a Board

Certified Pelvic Rehabilitation Practitioner (PRPC) through Herman and Wallace Pelvic Rehabilitation Institute. Erica is a faculty member at Herman and Wallace Pelvic Rehabilitation Institute and has authored the 2-day virtual course, Parkinson Disease and Pelvic Rehabilitation, developed for pelvic health clinicians to further their knowledge for best practice for this specialized population. Erica is certified in LSVT (Lee Silverman) BIG, delivering specialty Parkinson disease rehabilitative care

utilizing this intensive, amplitude, neuroplasticity, researched based exercise and functional protocol. Erica is an LSVT Global faculty member instructing the LSVT BIG training and certification course nationally and internationally, online webinars, and presenting yearly at the American Occupational Therapy Association (AOTA) national conference.  Erica partners with the Wisconsin Parkinson Association (WPA) as a support group and annual symposium speaker and authors publications in the

Wisconsin Parkinson Magazine.